Home › Drugs by Condition › D › Depression › Desvenlafaxine Pregnancy Warnings
Print Save or Share

Desvenlafaxine Pregnancy and Breastfeeding Warnings

Desvenlafaxine is also known as: Pristiq

Overview

Desvenlafaxine Extended-Release Tablets may cause harm to the fetus if it is used during the last 3 months of pregnancy. If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Desvenlafaxine Extended-Release Tablets while you are pregnant. Desvenlafaxine Extended-Release Tablets are found in breast milk. If you are or will be breast-feeding while you use Desvenlafaxine Extended-Release Tablets, check with your doctor. Discuss any possible risks to your baby.

Desvenlafaxine Pregnancy Warnings

Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during therapy. It should be noted that, in some cases, the clinical picture is consistent with serotonin syndrome. When treating a pregnant woman with desvenlafaxine during the third trimester, the physician should carefully consider the potential risks and benefits of treatment.

Desvenlafaxine has been assigned to pregnancy category C by the FDA. There are no controlled data in human pregnancy. Neonates exposed to SNRIs (Serotonin and Norepinephrine Reuptake Inhibitors), or SSRIs (Selective Serotonin Reuptake Inhibitors), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying. Desvenlafaxine should be used during pregnancy only if the potential benefits justify the potential risks.

Desvenlafaxine Breastfeeding Warnings

Desvenlafaxine is excreted into human milk. Because of the potential for serious adverse reactions in nursing infants from desvenlafaxine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Desvenlafaxine should only be administered to breastfeeding women if the expected benefits outweigh any possible risk.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This drug information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

(web4)